



2018 Annual Report

Division of Gastroenterology and Nutrition

DIVISION DESCRIPTION

The Division of Pediatric Gastroenterology and Nutrition cares for children with gastrointestinal and hepatologic disorders.

Nutritional services include placement and management of feeding tubes and support for underweight infants and children.

We also conduct clinical research and quality improvement for inflammatory bowel disease.

2018 HIGHLIGHTS

- Under the leadership of **Daniel O'Connell, MD**, division faculty are now participating in ImproveCareNow, a worldwide quality collaborative network that aims to improve care for children with Crohn's disease and ulcerative colitis, the two main types of inflammatory bowel disease (IBD).
 - In 2018, *U.S. News and World Report* ranked UW Health's American Family Children's Hospital in the [top 50 children's hospitals for gastroenterology and GI surgery](#).
-

RECENT PUBLICATIONS

Damodharan S, **Danko I**. Case 1: Hematemesis in a 30-month-old Boy. *Pediatr Rev*. 2018 Nov;39(11):560-561. doi: 10.1542/pir.2017-0290. PubMed PMID: 30385585.

Gumidyala AP, Greenley RN, Plevinsky JM, Pouloupoulos N, Cabrera J, Lerner D, Noe JD, **Walkiewicz D**, Werlin S, Kahn SA. Moving on: Transition readiness in adolescents and young adults with IBD. *Inflamm Bowel Dis*. 2018 Feb 15;24(3):482-489. doi: 10.1093/ibd/izx051. PubMed PMID: 29462383.

Riegert M, Peebles JK, **O'Connell DM**, Arkin LM. Visual diagnosis: A 7-year-old girl with labial edema and decreased growth velocity. *Pediatr Rev*. 2018 Dec;39(12):e57-e59. doi: 10.1542/pir.2017-0148. PubMed PMID: 30504258.

**ePub only; no print citation available when report was compiled*

*** Publication had previously appeared in 2017 report as an ePub*

GRANT SUPPORT

Principal Investigator	Sponsor	Title	Co-Investigators
O'Connell, Daniel M	University of Wisconsin Hospitals and Clinics	Improve Care Now	
Walkiewicz-Jedrzejczak, Dorota	Janssen Services, LLC	DEVELOP registry	
Walkiewicz-Jedrzejczak, Dorota	Janssen Research & Development	A phase 4, multicenter, open-label study of serum infliximab concentrations and efficacy and safety of dose escalation in pediatric patients with inflammatory bowel disease	